Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical Inc. have reported new antibody-drug conjugates consisting of single domain CUB domain-containing protein 1 (CDCP1)-targeting antibodies covalently linked to camptothecin derivatives through linkers potentially useful for the treatment of cancer.